University of Missouri-Columbia
Columbia, Missouri, 65212, United States
Location status: Recruiting
Location contact
Mary Beth Miller, PhD
CONTACT
Rebecca Patterson, BSc
CONTACT
NCT Number: NCT06286774
This project aims to evaluate improvement of insomnia as a mechanism of improvement in alcohol use outcomes.
Interested in participating?
Request Info18 year–49 year
All sexes
Interventional
Not applicable
Columbia, Missouri, 65212, United States
Location status: Recruiting
Mary Beth Miller, PhD
CONTACT
Rebecca Patterson, BSc
CONTACT
Heavy alcohol use is prevalent in the United States and results in significant physical and psychological burden. One in 10 adults in the United States reports binge drinking on a weekly basis, and few are willing to seek mental health treatment. Thus, additional strategies are needed to engage and treat individuals at risk for alcohol-related harm. Half of those who screen positive for hazardous drinking report clinically significant symptoms of insomnia. Insomnia tends to be less stigmatized than other mental health disorders, and it is one condition for which the field has highly efficacious treatment. Thus, one potential strategy to engage individuals in mental health treatment and reduce the burden of alcohol use in the United States is to target insomnia. This project aims (1) to examine change in insomnia as a mediator of insomnia treatment effects on alcohol use outcomes and sex as a moderator of those effects and (2) to identify mechanisms linking change in insomnia to alcohol use outcomes. Adults who drink alcohol and have insomnia will be randomly assigned to Cognitive Behavioral Therapy for Insomnia (CBT-I, n=112) or waitlist control (WLC, n=112). Outcomes will be assessed weekly during treatment, at the end of the active intervention period (post-treatment), and at 1-, 3-, and 6-month follow-ups.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Other names: CBT-I
Time frame: Change from baseline to mid-treatment (week 4) to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using Insomnia Severity Index (ISI). Response options range from 0 (not at all worried) to 4 (very much worried), with total scores ranging from 0 to 28 and higher scores indicating more severe insomnia.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using Timeline Followback and Daily Drinking Questionnaire. Typical weekly drinking quantity estimates will be summed to create a "drinks per week" total score, which will be used as our outcome variable.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using the Drinker Inventory of Consequences (DrINC). Scores range from 0 to 120, with higher scores indicating more consequences. The common consequence subscale scores range from 0 to 18.
Time frame: Change from baseline to post-treatment (week 6)
Assessed using a modified Treatment Willingness Scale. Participants rate their agreement with the statement that they would seek treatment for 5 medical and 5 mental health conditions if they experienced problems related to them. Willingness to seek alcohol or drug treatment is assessed on a 0-5 scale, with higher scores indicating greater willingness.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using the Penn Alcohol Craving Scale (PACS). PACS evaluates thoughts about drinking by assessing the duration, frequency, and intensity of such thoughts. Scores range 0-30, with higher scores indicating more severe craving.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Negative emotionality will be assessed as a latent construct of mood, anxiety, depression, PTSD symptoms, and difficulties with emotion regulation. Changes in individual symptoms will be reported for descriptive purposes.
Time frame: Change from baseline to post (week 6) to 3-month follow-up
Assessed using the Stroop Task. Average reaction time (RT; measured from color word/color rectangle stimuli onset until a response is made) on correct trials for each trial type (control trials, congruent trials, incongruent trials) were computed as the outcomes of interest. Higher RTs indicate worse performance.
Time frame: Change from baseline to post (week 6) to 3-month follow-up
Assessed using the N-Back Task. The dependent measure is the proportion of correct responses (yes and no) across all four blocks. Omissions are counted as errors.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using the Monetary Choice Questionnaire (MCQ). Participants indicate if they would rather receive a smaller amount of money now or a greater amount of money in a specified amount of time (e.g., 100 days, 2 days). The MCQ is scored using a logarithmic subject-specific discount rate (k variable). Higher k values indicate a greater preference for smaller, immediate rewards over larger, delayed reward.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using daily sleep diaries. The outcome will be percentage of days using alcohol to help with sleep.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using Fitbit Charge 6. Heart-rate variability (HRV) is an indicator of activity in the autonomic nervous system that quantifies changes in intervals between heart beats. In general, HRV increases with increasing parasympathetic activity, then plateaus and decreases with increasing sympathetic activity.
Time frame: Change from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups
Assessed using the revised Dysfunctional Beliefs and Attitudes about Sleep Scale. Responses range from 0 to 70, with higher scores indicating more dysfunctional beliefs.
Contact information is provided by the study sponsor or research team.
Mary Beth Miller Miller, PhD
CONTACT
Rebecca Patterson, BSc
CONTACT
University of Missouri-Columbia
Other
Sleep as a Mechanism of Change in Alcohol Use Outcomes Among Heavy-Drinking Adults
Acronym: ReTRAIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03804788
Alcohol; Harmful Use, Dyssomnias
Columbia, Missouri, United States
View Trial DetailsNCT03627832
Alcohol; Harmful Use, Dyssomnias
Columbia, Missouri, United States
View Trial DetailsNCT07735390
Dyssomnias, Insomnia
Tainan, Taiwan
View Trial DetailsNCT07299240
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial Details